Astria Therapeutics develops therapies for patients and families affected by allergic and immunologic diseases. Self-described as patient-focused, the company aims to bring life-changing treatments.

Astria Therapeutics, Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

COM:ASTRIATX

Astria Therapeutics

5.17

−0.77%

−0.04

Last Close

5.21

25/04 20:00

Market Cap

291.76M

Beta: -

Volume Today

286.12K

Avg: -

name

homepage url

country

employee count

sector

industry

Description

investor of

competitor of

Metrics